

CURRICULUM VITAE

Michael S. Ewer, M.D., M.P.H., J.D., LL.M., MBA, Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Internist and Professor (Previously tenured), Department of Cardiology; Division of Internal Medicine, University of Texas System Cancer Center, M. D. Anderson Hospital, Houston, TX (40% active)

Special Assistant to the Chief Experience Officer, The University of Texas MD Anderson Cancer Center, Houston, TX

Visiting Professor of Cardiology, University of Bern, Bern, Switzerland

Guest Professor of Law, University of Houston Health Law and Policy Institute, Houston, TX

Dual/Joint/Adjunct Appointment

Adjuvant Professor of Law, Mc George School of Law, N/A

Adjunct Professor of Law, Texas Southern University, HOUSTON, 77030

Professor (guest) University of Texas School of Public Health, Houston, TX

CITIZENSHIP

United States

HOME ADDRESS

3547 Sun Valley Drive
Houston, TX 77025
Phone: (713) 665-3353
Cell: 713-299-1260

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1485
Houston, TX 77030
Room Number: FCT18.5000 Unit 1485
Phone: (713) 745-2216
Fax: (713) 792-0795

EDUCATION

Degree-Granting Education

Hunter College, Bronx, NY, BA, 1964

University of Basel, Basel, Switzerland, MD, 1969, Medicine

University of Texas, School of Public Health, Houston, TX, MPH, 1989, Master of Public Health

University of Houston Law Center, Houston, TX, JD, 2001, Doctor of Jurisprudence

University of Houston Law Center, Houston, TX, LL.M., 2005, Master of Law

Texas Women's University, Houston, TX, MBA, 2008, Master of Business Administration

The University of Texas Houston, School of Public Health, Houston, TX, Ph.D., Health Management (2017)

Postgraduate Training

Rotating Clinical Internship, Norwalk Hospital, Norwalk, CT, 1970-1971

Junior Residency, Norfolk General Hospital, Norfolk, VA, 1971-1972
Diploma of Tropical Medicine, Swiss Tropical Institute, Basel, Switzerland, 1972-1973
Senior Residency, Pawtucket Memorial Hospital - Brown University, Pawtucket, RI, 1974-1975
Chief Resident, Pawtucket Memorial Hospital - Brown University, Pawtucket, RI, 1974-1975
Fellowship, Cardiology, Baylor University Medical Center, Dallas, TX, 1975-1977
M.P.H. Degree, University of Texas, School of Public Health, Houston, TX, 1987-1989
Doctor of Jurisprudence (J. D.), University of Houston Law Center, 1996-2001
Master of Law (L.L.M.), University of Houston Law Center, 2001-2004

CREDENTIALS

Board Certification

American Board of Internal Medicine, 1980

Licensures

Active

Texas Granted upon reciprocity with Connecticut, TX, E 5064, 12/1975

Inactive

NY

VA

CT (FLEX examination, 1970)

AMERICAN HEART ASSOCIATION CERTIFICATION:

Basic and Advanced Cardiac Life Support (current)

TEACHING EXPERIENCE (Student evaluations available on request)

Medical

Electrocardiography

Clinical assessment

Medical Ethics and Quality of Care

Rational Use of Health Resources

Legal

Health Law (Foundations)

HIPAA (Patient Privacy)

Public Health Law

Hospital Law and Ethics

Advanced Health Law

EXPERIENCE/SERVICE

Academic Appointments

Teaching Fellow, Brown University, Providence, RI, 1974-1975

Faculty Associate and instructor in Medicine, MD ANDERSON HOSPITAL, HOUSTON, TX, 1978-1979

Assistant Internist and Assistant Professor of Medicine, MD ANDERSON HOSPITAL, HOUSTON, TX, 1979-1983

Associate Internist and Assistant Professor of Medicine, MD ANDERSON HOSPITAL,
HOUSTON, TX, 1983-1984

Associate Internist and Associate Professor of Medicine (Tenured), MD ANDERSON HOSPITAL,
HOUSTON, TX, 1984-1989

Affiliate Faculty, Advanced Cardiac Life Support Program, American Heart Association,
HOUSTON, TX, 1986-1996

Instructor, San Jacinto College, HOUSTON, TX, 1987-1991

Internist and Associate Professor of Medicine (Tenured), MD ANDERSON HOSPITAL,
HOUSTON, TX, 1989-2002

Internist and Professor (Previously tenured), Division of Internal Medicine, University of Texas
System Cancer Center, M. D. Anderson Hospital, Houston, TX, 9/2002-present

Visiting Professor of Cardiology, University of Bern, Bern, Switzerland, 2005-present

Guest Professor of Law, University of Houston Health Law and Policy Institute, Houston, TX,
8/2006-present

Internist and Professor (Non-tenured part-time), MD ANDERSON HOSPITAL, HOUSTON, TX,
2013-present

Adjunct Professor of Law, Texas Southern University, HOUSTON, 77030, 2014

Adjuvant Professor of Law, Mc George School of Law, N/A, 2015-2017

Professor, University of Texas School of Public Health, Houston, TX, 2018

Administrative Appointments/Responsibilities

Medical Director of the Medical Intensive Care Unit, The University of Texas M D Anderson
Cancer Center, Houston, TX, 1983-1993

Special Assistant to the Vice President for Patient Care, The University of Texas MD Anderson
Cancer Center, Houston, TX, 1994-1997

Special Assistant to the Vice President for Patient Care, The University of Texas MD Anderson
Cancer Center, Houston, TX, 1994-1997

Deputy Section Chief, Cardiology Section, The University of Texas MD Anderson Cancer Center,
Houston, TX, 1996-2000

Special Assistant to the Physician-in-Chief, The University of Texas MD Anderson Cancer Center,
Houston, TX, 1997-2000

Physician Liaison, Medical Affairs, The University of Texas MD Anderson Cancer Center,
Houston, TX, 2000-2005

Special Assistant to the Chief Experience Officer, The University of Texas MD Anderson
Cancer Center 2019-present

Other Appointments/Responsibilities

N/A

Endowed Positions

N/A

Consultantships

Hermann Hospital, Houston, TX, Consultant, Member and Consultant of the Hermann Hospital
Ethics Committee, 1990-1997

Smith-Kline Beecham dba Glaxo-Smith Kline, Philadelphia, PA, Consultant, 2/2008-2/2009

Pfizer Labs, New York, NY, Consultant, 2/2009-2012

Sanofi-Aventis, Bridgewater, NJ, Consultant, 4/2009-4/2010

Genentech, San Francisco, CA, Consultant, 5/2009-5/2010

AstraZeneca, Wilmington, DE, Consultant, 5/2009-present
Methylgene, Montreal, Canada, Consultant, 7/2009-7/2010
MERCK, Darmstadt, Germany, Consultant, 5/2010-5/2011
F. Hoffman La Roche, N/A, Consultant
GlaxoSmithKline, N/A, Consultant
Dalcath, N/A, Consultant
Pharmacyclies, N/A, Consultant
National Surgical Adjuvant Breast and Bowel Project (NSABP), us, Consultant
Breast Cancer International Research Group (BCIRG), US, Consultant
Bohringer-Ingelheim, US, Consultant
Supratek Pharma, Quebec, Canada, Consultant
Bayer Pharmaceuticals, Germany

Military or Other Governmental Service

N/A

Institutional Committee Activities

Medical Intensive Care Unit Committee, Chairman, 1983-1993
Cardiopulmonary Resuscitation Committee, Chairman, 1983-1997
Ethics Committee, Member, 1985-1993
Product Standards Committee, Member, 1986-1988
Disaster Committee, Chairman, 1988-1989
Ethics Committee, Chairman, 1988-1993
Hermann Hospital Ethics Committee, Member and Ethics Consultant, 1990-1997
Professional Liability Committee, Member, 1995-present
Conflict of Interest Committee, Member, 2000-2006
Conflict of Interest Committee, Vice Chair, 2002-2003
Conflict of Interest Committee, Chair, 2003-2005
Credentials Committee of the Medical Staff, Member, 2004-2013
Uncompensated Care Committee, Member, 2005-present
Grievance Review Board, Member, 9/2008-present
Disclosure and Apology Committee, Chair, 4/2010-2018
Pharmacy and Therapeutics Committee, Member, 2013-present
Pharmacy Escalation Committee, Member, 2015-present

HONORS AND AWARDS

Special Recognition Award, Norwalk Hospital, Norwalk, Connecticut, 1971
Special Recognition Award, Norwalk Hospital, Norwalk, Connecticut, 1971

RESEARCH

Grants and Contracts

Funded

N/A

Pending

N/A

Other

N/A

Completed

N/A

Not Funded

N/A

Protocols

Funded

N/A

Unfunded

A CLINICAL AND NONINVASIVE ASSESSMENT OF LONG-TERM CARDIAC EFFECTS OF DOXORUBICIN IN ADULT SURVIVORS OF BREAST CANCER, DM93-019

A COMPARATIVE STUDY OF TAXOL AND PARENTERAL HYDROXYUREA IN PATIENTS WITH CISPLATIN/CARBOPLATIN REFRACTORY OVARIAN CANCER, ID91-009

A PHASE I STUDY EVALUATING THE PHARMACOKINETIC AND CARDIAC SAFETY OF HERCEPTIN (TRASTUZUMAB) ADMINISTERED IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE IN WOMEN WITH HER2 OVEREXPRESSION METASTATIC BREAST CANCER, ID 99-287

A PRELIMINARY ASSESSMENT OF THE VALUE OF ECHOCARDIOGRAPHIC AND DOPPLER STUDIES IN THE HEMODYNAMIC ASSESSMENT AND MANAGEMENT OF PATIENTS IN SHOCK, DM91-044

A STUDY OF THE EFFECT OF ADRIAMYCIN ON CARDIAC PERFORMANCE USING NONINVASIVE TECHNIQUES: DETECTING EARLY CARDIOTOXICITY BY ECHOCARDIOGRAPHIC DOPPLER MEASUREMENT OF DIASTOLIC VENTRICULAR FUNCTION, DM90-051

CARDIAC MONITORING OF PATIENTS TREATED WITH DIHYDROXYANTHRACENEDIONE (MITOXANTRONE), DM81-68

EFFICACY OF POLYURETHANE TRIPLE LUMEN CATHETERS COATED WITH AG?1000 AT PREVENTING CATHETER-RELATED INFECTIONS: A RANDOMIZED DOUBLE-BLIND STUDY, DM91-005

PHASE I CLINICAL AND PHARMACOLOGY STUDY OF COMPOUND LY195448, DM86-94

PHASE I CLINICAL AND PHARMACOLOGY STUDY OF THP-ADRIAMYCIN (4-O-TETRAHYDROPRYANYL-ADRIAMYCIN HYDROCHLORIDE), DM85-66

PHASE I EVALUATION OF EXTRACORPOREAL IMMUNADSORPTION WITH PROSORBA COLUMNS, DM84-11

PHASE I STUDY OF TAXOL WITH MITOXANTRONE AND MESNA/IFOSFAMIDE FOR PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA, DM93-098

PHASE I TRIAL OF SCH 34900 RECOMBINANT INTERLEUKIN-4 (RHUIL-4) IN PATIENTS WITH METASTATIC MELANOMA, DM92-101

PHASE I-II STUDY OF HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, CISPLATIN (CVP) FOLLOWED BY MITOXANTRONE, THIOTEPA (MT) WITH AUTOLOGOUS MARROW SUPPORT FOR RELAPSED BREAST CANCER, DM89-121

PHASE I-II STUDY OF NG-MONOMETHYL-L-ARGININE (NMA) IN PATIENTS WITH REFRACTORY SEPTIC SHOCK, DM93-069

PHASE II PILOT STUDY OF THE THP-ADRIAMYCIN IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, DM87-011

PHASE II STUDY OF AG-IDA-DEXNIGULDIPINE IN PATIENTS WITH FLAG-IDA OR AG-IDA REFRACTORY AML OR MDS, DM94-093

PHASE II STUDY OF IV MENOGARIL IN PRIMARY MALIGNANT BRAIN TUMORS, DM88-007

PHASE II STUDY OF MITOXANTRONE ADMINISTERED BY 14-DAY CONTINUOUS INFUSION IN PATIENTS WITH METASTATIC BREAST CANCER, DM90-112

PHASE II STUDY OF TAXOL WITH MITOXANTRONE, MESNA AND IFOSFAMIDE (MINT) FOLLOWED BY CONSOLIDATION WITH ESHAP FOR PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA AND NO PRIOR ARA-C/CISPLATIN (A/P) COMBINATION THERAPY, DM94-040

PHASE II STUDY OF TAXOL WITH MITOXANTRONE, MESNA AND IFOSFAMIDE (MINT) FOR PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA AND PRIOR ARA-C/CISPLATIN (A/P) COMBINATION THERAPY, DM94-041

PHASE II STUDY OF TLC D-99 (LIPOSOMAL DOXORUBICIN), 5FU AND CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC BREAST CANCER, DM92-014

RANDOMIZED PHASE II STUDY OF DOXORUBICIN AND PACLITAXEL BY TWO DIFFERENT SCHEDULES FOR PATIENTS WITH STAGE IV BREAST CANCER, DM95, PI - GABRIEL N. HORTOBAGYI

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Ewer MS. *Zur Fruhentwicklung des Stroma Cornea und der Pupilmembran beim Menschen* [Early development of the stroma cornea and the pupillary membrane in man]. *Acta Anat (Basel)* 75(1):37-46, 1970. PMID: 5474731.
2. Ali, MK, Mountain CF, Ewer MS, Johnston DA, Haynie TP. The prediction of pulmonary function loss after lung resection for bronchogenic carcinoma. *Chest*:337 42, 1980.
3. Rosi DR, Nogeire C, Brown B, Ali M, Ewer M, Samuels M. 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. *Cancer* 48(1):21-5, 7/1981. PMID: 7237386.
4. B MacKay, LM Keyes, RS Benjamin MS Ewer, SS Legha, S Wallace. *Cardiac Biopsy Texas Society for Electron Microscopy* 11:7-15, 1981.
5. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. *Ann Intern Med* 96(2):133-9, 2/1982. PMID: 7059060.
6. Ewer MS, Ali MK, Frazier OH. Open chest resuscitation for cardiopulmonary arrest related to mechanical impairment of circulation: a report of two cases. *Crit Care Med* 10(3):198-9, 3/1982. PMID: 7060390.
7. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. *Cancer* 49(9):1762-6, 5/1982. PMID: 7074581.
8. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, Ali MK. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. *Ann N Y Acad Sci* 393:411-8, 1982. PMID: 6959564.

9. Dixon C, Ali MK, Atallah MR, Ewer MS. Postresection bronchopleural fistula: detection by regional ventilation-perfusion studies. *South Med J* 76(4):485-6, 4/1983. PMID: 6836364.
10. Ali MK, Buzdar AU, Ewer MS, Cheng RS, Haynie TP. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. *J Surg Oncol* 23(3):212-6, 7/1983. PMID: 6865442.
11. Ali MK, Ewer MS, Atallah MR, Mountain CF, Dixon CL, Johnston DA, Haynie TP. Regional and overall pulmonary function changes in lung cancer. Correlations with tumor stage, extent of pulmonary resection, and patient survival. *J Thorac Cardiovasc Surg* 86(1):1-8, 7/1983. PMID: 6865454.
12. Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, Benjamin RS, Haynie TP. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. *J Clin Oncol* 2(2):112-7, 2/1984. PMID: 6699662.
13. Valdivieso M, Burgess MA, Ewer MS, Mackay B, Wallace S, Benjamin RS, Ali MK, Bodey GP, Freireich EJ. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. *J Clin Oncol* 2(3):207-14, 3/1984. PMID: 6321689.
14. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. *Cancer Treat Rep* 68(9):1085-91, 1984. PMID: 6478448.
15. McKenna RJ, Ali MK, Ewer MS, Frazier OH. Pleural and pericardial effusions in cancer patients. *Curr Probl Cancer* 9(6):1-44, 6/1985. PMID: 3896666.
16. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M. Doxorubicin-induced congestive heart failure in adults. *Cancer* 56(6):1361-5, 1985. PMID: 4027874.
17. Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Holmes F. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. *Invest New Drugs* 3(2):117-21, 1985. PMID: 4019116.
18. MS Ewer, SP Chawla, CH Carrasco, B MacKay, MK Ali, TP III Haynie, RS Benjamin. University of Tokyo Press. Correlations of ejection fraction and biopsy grades in patients receiving Adriamycin:251-2, 1985.
19. Ewer MS, Ali MK, Atta MS, Morice RC, Balakrishnan PV. Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure. *JAMA* 256(24):3364-6, 12/1986. PMID: 3783887.
20. Holmes FA, Glass JP, Ewer MS, Terjanian T, Tetu B. Syncope and hypotension due to carcinoma of the breast metastatic to the carotid sinus. *Am J Med* 82(6):1238-42, 6/1987. PMID: 3037898.
21. Ali MK, Ewer MS, Balakrishnan PV, Ochoa DA, Morice RC, Raizner AE, Lawrie GM. Balloon angioplasty for superior vena cava obstruction. *Ann Intern Med* 107(6):856-7, 12/1987. PMID: 2961296.
22. Ali MK, Ewer MS, Cangir A, Fisher DJ. Coronary artery embolism following cancer chemotherapy. *Am J Pediatr Hematol Oncol* 9(3):200-3, 1987. PMID: 3674331.
23. MS Ewer, MK Ali, MS Atta, RC Morice, PV Balakrishnan. Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure 8:32-4, 1987.
24. Ewer MS, Ali MK. Critical cardiologic considerations in the cancer patient. *Crit Care Clin* 4(1):41-60, 1/1988. PMID: 3061579.
25. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Frascini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. *Cancer* 63(1):37-45, 1/1989. PMID: 2910423.
26. Hortobagyi GN, Yap HY, Kau SW, Frascini G, Ewer MS, Chawla SP, Benjamin RS. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. *Am J Clin Oncol* 12(1):57-62, 2/1989. PMID: 2643296.
27. Kim EE, Wallace S, Abello R, Coan JD, Ewer MS, Salem PA, Ali MK. Malignant cardiac fibrous histiocytomas and angiosarcomas: MR features. *J Comput Assist Tomogr* 13(4):627-32, Jul-Aug, 7/1989. PMID: 2545752.
28. Ewer MS. Philosophy of care, decision making, and ethical considerations. *Crit Care Clin* 5(3):679-95, 7/1989. PMID: 2670098.

29. Truett L, Ewer MS. Shock: managing the septic syndrome in patients with cancer. *Dimens Oncol Nurs* 3(4):9-13, 1989. PMID: 2638165.
30. Ewer MS, Ali MK. Surgical treatment of the cancer patient: preoperative assessment and perioperative medical management. *J Surg Oncol* 44(3):185-90, 7/1990. PMID: 2196400.
31. Shin DM, Kramer AM, Dimery IW, Raber MN, Ewer M, Hong WK. Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck. *Invest New Drugs* 9(1):89-91, 1991. PMID: 2026488.
32. Gibbs HR, Swafford J, Nguyen HD, Ewer MS, Ali MK. Postoperative atrial fibrillation in cancer surgery: preoperative risks and clinical outcome. *J Surg Oncol* 50(4):224-7, 8/1992. PMID: 1640704.
33. Ewer MS, Ali MK, Gibbs HR, Swafford J. Nodus migrans: the case of the migrating knot. *Am J Crit Care* 1(2):108-10, 9/1992. PMID: 1339173.
34. Mackay B, Ewer MS, Carrasco CH, Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. *Ultrastruct Pathol* 18(1-2):203-11, Jan-Apr, 1/1994. PMID: 8191628.
35. Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff KL. Late Doxorubicin-Associated Cardiotoxicity in Children: The Possible Role of Intercurrent Viral Infection. *Cancer* 74(1):182-8, 7/1994. PMID: 8004574.
36. Massin EK, Zeluff BJ, Carrol CL, Radovancevic B, Benjamin RS, Ewer MS, Bransford TL, Buja LM. Cardiac transplantation and aspergillosis. *Circulation* 90(3):1552-6, 9/1994. PMID: 8087962.
37. Ewer MS, Ali MK, Gibbs HR, Swafford J, Graff KL, Cangir A, Jaffe N, Thapar MK. Cardiac Diastolic Function in Pediatric Patients Receiving Doxorubicin. *Acta Oncol* 33(6):645-649, 1994. PMID: 7946442.
38. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. *Crit Care Med* 23(6):1018-24, 6/1995. PMID: 7774211.
39. Ewer MS, Taubert JK. Advance directives in the intensive care unit of a tertiary cancer center. *Cancer* 76(7):1268-74, 10/1995. PMID: 8630908.
40. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. *J Clin Oncol* 13(11):2827-34, 11/1995. PMID: 7595745.
41. Kilbourn, RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis C. Ng-monomethyl-L-arginine, an inhibitor of nitric oxide synthase, reverses Interleukin-2-induced hypotension. *Crit Care Med* 23:1018-1024., 1995.
42. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchini JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 15(4):1318-32, 4/1997. PMID: 9193323.
43. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchini JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. *J Clin Oncol* 15(4):1333-40, 4/1997. PMID: 9193324.
44. Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. *Med Pediatr Oncol* 31(6):512-5, 12/1998. PMID: 9835904.
45. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? *Semin Oncol* 26(4 Suppl 12):96-101, 8/1999. PMID: 10482200.
46. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. *Cancer Chemother Pharmacol* 43(6):471-8, 1999. PMID: 10321507.
47. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-

- encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. *J Clin Oncol* 17(5):1425-34, 1999. PMID: 10334527.
48. Ewer MS. The definition of medical futility: Are we trying to define the wrong term? *Heart Lung* 30(1):3-4, Jan-Feb, 1/2001. PMID: 11174361.
 49. Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. *Oncol Rep* 8(3):611-4, May-Jun, 5/2001. PMID: 11295089.
 50. Ewer MS, Kish SK, Martin CG, Price KJ, Feeley TW. Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation. *Cancer* 92(7):1905-12, 10/2001. PMID: 11745264.
 51. Wallace SK, Ewer MS, Price KJ, Feeley TW. Outcome and cost implications of cardiopulmonary resuscitation in the medical intensive care unit of a comprehensive cancer center. *Support Care Cancer* 10(5):425-9, 7/2002. e-Pub 4/2002. PMID: 12136227.
 52. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. *Clin Cancer Res* 11:3360-8, 2002.
 53. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer* 97(11):2869-79, 6/2003. PMID: 12767102.
 54. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation* 109(25):3122-31, 6/2004. PMID: 15226229.
 55. Ewer MS. Exercise echocardiography reflects cumulative anthracycline exposure during childhood. *Pediatr Blood Cancer* 42(7):554-5, 6/2004. PMID: 15127408.
 56. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. *Semin Oncol* 31(6 Suppl 13):161-81, 12/2004. PMID: 15717742.
 57. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *J Clin Oncol* 23(13):2900-2, 5/2005. PMID: 15860848.
 58. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Puztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23(16):3676-85, 6/2005. e-Pub 2/2005. PMID: 15738535.
 59. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol* 23(31):7820-6, 11/2005. PMID: 16258084.
 60. Tan-Chiu e, Yothers G, Romond E, Geyer Jr. CE, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Deay TE, Pastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. *J Clin Oncol* 23:7811-19, 2005.
 61. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. *Expert Rev Anticancer Ther* 6(9):1249-69, 9/2006. PMID: 17020459.
 62. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 5(6):791-809, 11/2006. PMID: 17044806.
 63. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Puztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. *Clin Cancer Res* 13(1):228-33, 1/2007. PMID: 17200359.

64. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. *Clin Breast Cancer* 8(8):600-607, 6/2007. PMID: 17592672.
65. Ewer MS. The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight. *Eur J Cancer* 43(14):2024-5, 9/2007. e-Pub 8/2007. PMID: 17719769.
66. Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? *J Clin Oncol* 25(34):5532-3; author reply 5533-4, 12/2007. PMID: 18048835.
67. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. *Int J Nanomedicine* 2(4):567-83, 2007. PMCID: PMC2676818.
68. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? *J Clin Oncol* 26(8):1201-1203, 3/2008. e-Pub 1/2008. PMID: 18227525.
69. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. *Mayo Clin Proc* 83(6):679-86, 6/2008. PMID: 18533085.
70. Ewer MS, Lenihan DJ, Khakoo AY. Sunitinib-related cardiotoxicity: An interdisciplinary issue. *Nat Clin Pract Cardiovasc Med* 5(7):364-365, 7/2008. e-Pub 5/2008. PMID: 18490940.
71. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. *Drug Saf* 31(6):459-467, 2008. PMID: 18484781.
72. Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. *Cancer* 115(9):1813-26, 5/2009. e-Pub 2/2009. PMID: 19235248.
73. Ewer MS, Ewer SM. Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data. *J Clin Oncol* 27(36):6073-6075, 12/2009. e-Pub 11/2009. PMID: 19901128.
74. Ewer SM, Ewer MS. Anthracycline cardiotoxicity: Why are we still interested? *Oncology* 23(3):234-239, 2009.
75. DiLorenzo G. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. *Ann Oncol* 20(9):1535-1542, 2009.
76. Pollock RE, Ewer MS. The integrity of authorship: doing the right thing. *Cancer* 116(17):3986-7, 9/2010. e-Pub 6/2010. PMID: 20564144.
77. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol* 7(10):564-75, 10/2010. PMID: 20842180.
78. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 13(1):1-10, 1/2011. PMID: 21169385.
79. Tortorella FR, Ewer MS, Douglas-Ntagha PB, Harper G, Walters R, Ecung WB. Developing a transfer center in a tertiary cancer center: streamlining access and communication to accommodate increasing demand for service. *J Healthc Manag* 56(3):199-210; discussion 210-1, May-Jun, 5/2011. PMID: 21714374.
80. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? *Ann Oncol* 22(5):1011-8, 5/2011. e-Pub 11/2010. PMID: 21097988.
81. Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. *Ann Oncol* 22(6):1250-8, 6/2011. e-Pub 11/2010. PMID: 21112929.
82. Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. *Heart Fail Clin* 7(3):363-72, 7/2011. e-Pub 5/2011. PMID: 21749888.
83. Ewer MS, Swain SM, Cardinale D, Fadol A, Suter TM. Cardiac dysfunction after cancer treatment. *Tex Heart Inst J* 38(3):248-52, 2011. PMCID: PMC3113132.
84. Ewer MS, Yang M, Buzdar AU. Screening for cardiac risk before anthracycline administration: what are the real benefits? *Clin Breast Cancer* 12(1):1-3, 2/2012. e-Pub 11/2011. PMID: 22130035.

85. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. *Eur Heart J*. e-Pub 7/2012. PMID: 22789916.
86. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. *Ann Oncol* 23(11):2960-3, 11/2012. e-Pub 6/2012. PMID: 22745218.
87. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. *J Clin Oncol* 30(31):3792-9, 11/2012. e-Pub 9/2012. PMID: PMC3478574.
88. Ewer MS, Ewer SM. Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity. *Expert Opin Drug Saf* 12(5):611-4, 9/2013. e-Pub 8/2013. PMID: 23931567.
89. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. *Lancet Oncol* 14(13):1317-25, 12/2013. e-Pub 11/2013. PMID: PMC4176878.
90. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. *Oncologist* 18(3):257-64, 2013. e-Pub 3/2013. PMID: PMC3607520.
91. Kim PY, Ewer MS. Chemotherapy and QT Prolongation: Overview With Clinical Perspective. *Curr Treat Options Cardiovasc Med* 16(5):303, 5/2014. PMID: 24733423.
92. Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. *PLoS One* 9(9):e107903, 2014. e-Pub 9/2014. PMID: PMC4177865.
93. Ewer MS, Suter TM, Lenihan DJ, Liviu N, Breazna A, Demetri GD, Motzer RJ. Cardiovascular Events Among 1,090 Cancer Patients Treated with Sunitinib, Interferon, or Placebo: a Comprehensive Adjudicated Database Analysis Demonstrating Clinically Meaningful Reversibility of Cardiac Events. *Eur J Cancer*, 2014.
94. Ewer MS, Ewer SM, Suter Tm. Cardiotoxicity in adults: An update. *Pediatric Cardiology* 36:57-59, 2014.
95. Kim PY, Ewer MS. Chemotherapy and QT Prolongation: Overview iwht Clinical Perspective. *Curr Treat Options Cardio Med*, (Published online: 25 April 2014), 2014.
96. Ruiz JN, Belum VR, Creel P, Cohn A, Ewer M, Lacouture ME. Current Practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: A national survey of oncologist. *Clin Genitourinary Cancer*, 2014.
97. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said Rabih, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response i cancer patients treated with anti-vascular endothelial growth factor therapy. *Invest New Drugs* 32:717-22, 2014.
98. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicara R, Villarraga HR, Lancellotti P. Expert consensus for multimodality

- imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr, European Heart Journal Eur Hear J Cardiovasc Imaging* 27:911-39, 2014.
99. Gianni L, Pane M, Sandri T, Steiner RK5 Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LCM, Lenihan DJ, Sallan SE, Sawyer DV, Suter, TM, Swain SM, Van Leeuwen FE. Report on the International Colloquium on Cardio-Oncology. *Ecancermedicalsecience* 2014:8:533, 2014.
 100. Ewer MS, Patek K, O'Brien D, Lorence RM. Cardiac safety of afatinib: a review of data from clinical trials. *Cardio-Oncology* 1:1-8, 2015.
 101. Petek BJ, Greenman C, Herrmann J, Ewer MS, Jones RL. Cardio-oncology: an ongoing evolution. *Future Oncol* 11:2059-66, 2015.
 102. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. *Nat Rev Cardiol* 12:547-58, 2015.
 103. Ewer MS, Ewer SM. The anthracycline-trastuzumab interaction: a lesson in not jumping to confusion. *Trends Pharmacol Sci* 36:321-2, 2015.
 104. Ewer MS, Swain SM. Enhanced cardiac testing in a dual anti-HER2 regimen: what have we learned. *The Oncologist* 21:1-3, 2016.
 105. Ewe MS, Banchs J. Strain Echocardiography: Is routine strain analysis ready for Clinical purposes? *JACC*, 2017.
 106. Swain SM, Ewer MS, Viale G, Delalogue S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C, BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. *Ann Oncol* 29(3):646-653, 3/2018. PMID: PMC5888999.
 107. Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). *Breast Cancer Res Treat* 168(3):631-638, 4/2018. e-Pub 12/2017. PMID: PMC5843537.
 108. Ewer MS, Herson J. False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters. *Chemotherapy* 63(6):324-329, 2018. e-Pub 3/2019. PMID: 30844801.
 109. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. *Br J Haematol* 184(4):558-569, 2/2019. e-Pub 12/2018. PMID: PMC6587776.
 110. Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. *Clin Lymphoma Myeloma Leuk* 19(3):135-141, 3/2019. e-Pub 11/2018. PMID: PMC6642803.
 111. Ewer MS, Ewer SM. Trastuzumab Cardiotoxicity After Anthracycline Exposure Constitutes a Complex and Clinically Important Entity. *JACC Heart Fail* 7(9):805-807, 9/2019. e-Pub 8/2019. PMID: 31401098.
 112. Armenian SH, Jurczak W, Carver JR, Gennari A, Minotti G, Ewer MS. Helping the cardio-oncologist: from real life to guidelines. *Semin Oncol* 46(6):433-436, 12/2019. e-Pub 11/2019. PMID: 31784041.
 113. Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. *Oncology. Semin Oncol* 46(6):397-402, 12/2019. e-Pub 11/2019. PMID: 31753424.

114. Ewer MS, Carver JR, Minotti G. Old and new directions of Cardio-Oncology. *Semin Oncol* 46(6):395-396, 12/2019. e-Pub 11/2019. PMID: 31767271.
115. Lestuzzi C, Annunziata MA, Nohria A, Muzzatti B, Bisceglia I, Ewer MS. Cancer patients in cardiology: how to communicate with patients with special psychological needs and manage their cardiac problems in daily clinical practice. *J. Cardiovasc Med* 21:286-291, 2020.
116. Eiger D, Ponde NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers Fs, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Lang I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. *Br J Cancer* 122:1453-1460, 2020.
117. Fadol AP, Palaskas NL, Ewer MS, Deswal A. An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. *Cardiooncology*. 2020 15;6:20.
118. Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac Safety of Osimertinib: A Review of Data. *J Clin Oncol*. 2021; 39:328-337.
119. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. *J Clin Oncol*. 2021: JCO2001204. doi:
120. Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M; ALTTO Steering Committee and Investigators. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). *Eur J Cancer*. 2021;148:287-296.
121. Ewer MS. Reply to K. Anand et al and K. Kunimasa. *J Clin Oncol*. 2021 Jun 20;39(18):2051-2052. doi: 10.1200/JCO.21.00502.
122. Ewer MS, Ewer SM. Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC. *JTO Clin Res Rep*. 2021 Oct 13;2(10):100233. doi: 10.1016/j.jtocrr.2021.100233. PMID: 34704082; PMCID: PMC8527046.
123. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. *J Clin Oncol*. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4. PMID: 33539215.
124. Ewer MS, Herson J. Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports. *Cardiooncology*. 2022 Jul 19;8(1):13. doi: 10.1186/s40959-022-00139-w. PMID: 35854393; PMCID: PMC9295280.
125. Ewer MS, Swain SM. Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact? *J Clin Oncol*. 2022 Jul 25:JCO2201006. doi: 10.1200/JCO.22.01006. Epub ahead of print. PMID: 35878103.

Invited Articles

1. Ali, MK, Mountain CF, Khalil KG, Ewer MS, Soto A. A segmental formula for the prediction of pulmonary function following lobectomy and pneumonectomy in man. *The Cancer Bulletin* 31:93, 1979.

2. Ali, MK, Bekheit Saad S, Ewer MS, Soto A, Buzdar AU, Blumenschein GR, Tashima CK, Wiseman CL, Hortobagyi GN, Maroongroge DP. Noninvasive evaluation of myocardial function in patients receiving Adriamycin chemotherapy. *The Cancer Bulletin* 31:93, 1979.
3. Ali MK, Ewer MS. Preoperative cardiopulmonary evaluation of patients undergoing surgery for lung cancer. *The Cancer Bulletin* 32:100, 1980.
4. Ewer MS, Ali MK. Cardiac Biopsy: A review of the procedure complications and indications. *Practical Cardiology* 7:143-54, 1981.
5. Ali MK, Mountain C, Ewer MS, Johnston D, Haynie TP. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma In: Clark RL, Cumley RW, Hickey RC. *The Year Book of Cancer* 5:68-70, 1981.
6. Legha, SS, Benjamin RS, Ewer M, Mackay B, Wallace S, Hortobagyi GN, Freireich EJ. Continuous intravenous infusion of adriamycin. Evaluation of its efficacy and toxicity. *Proceedings of the International Symposium on Adriamycin*, 1983.
7. Chawla, SP, Benjamin RS, Ewer MS, Hortobagyi GN, Legha SS, MacKay B, Ali MK, Carrasco CH, Wallace S, Haynie TP III, Freireich EJ. High cumulative dose Adriamycin treatment beyond the conventional limits of 500 mg/m² and reduction of cardiotoxicity by continuous infusion schedule. *13th International Congress of Chemotherapy*:4-8, 1983.
8. Chawla, SP, Benjamin RS, Legha SS, Ewer MS, Ali MK, MacKay B, Carrasco DH, Hortobagyi GN, Wallace S, Haynie TP III, Freireich EJ. Role of cardiac biopsy and radionuclide scan in monitoring of Adriamycin induced cardiotoxicity. *13th International Congress of Chemotherapy*:1-3, 1983.
9. Ali, MK, Ewer MS, McKenna Jr RJ. Critical cardiopulmonary problems in the cancer patient. *The Cancer Bulletin* 36:128-34, 1984.
10. Ewer MS, Ali MK. Critical care for the cancer patient. *The Cancer Bulletin* 36:125, 1984.
11. Mansour, G, Ewer MS, Trinidad E, Wyllie C. Guidelines for nutritional support of the critically ill cancer patient. *The Cancer Bulletin* 36:152-5, 1984.
12. Ewer MS, Ali MK. Optimal use of the Medical Intensive Care Unit The University of Texas M. D. Anderson Hospital Experience. *The Cancer Bulletin* 36:126-7, 1984.
13. Ewer, MS, Ali MK, Balakrishnan PV. Clinical recognition of carcinoid heart disease in the elderly. *Geriatric Medicine Today* 4:23-30, 1985.
14. Ewer, MS, Clarke VM, Horowitz L. Critical care for the aplastic anemia patient. *The Cancer Bulletin* 37:245-7, 1985.
15. Benjamin, RS, Holmes F, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Dukart G, Bodey GP. Evaluation of novantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. *Proceedings of the Current Status of Novantrone*:69-73, 1985.
16. McKenna, RJ, Ali MK, Ewer MS, Frazier OH. Pleural and pericardial effusions in cancer patients. *Current Problems in Cancer* 9:44, 1985.
17. Ewer MS, Mansour G. Critical care treatment of the cancer patient: Preserving the quality of life. *The Cancer Bulletin* 36:261-3, 1986.
18. Ewer MS. Alcohol and breast cancer new concerns. *Internal Medicine World Report*:2-3, 1987.
19. Feinberg, BA, Ewer MS, Batizy S, Buzdar AV. Clostridium perfringens infection of the pericardium: A rare form of septic pericarditis. *The Cancer Bulletin* 39:116-7, 1987.
20. Ewer MS, Ali MK. Critical care for the cancer patient cardiologic considerations. *Critical Care Clinics of North America* 4:41-60, 1988.
21. Truett L, Ewer MS. Pericardial effusion with tamponade: Relief for the symptomatic patient". *Dimens Oncol Nurs* 2(3):11, 1988. PMID: 3251539.
22. Ewer MS. Psyllium hydrophilic mucilloid: More than just a natural fiber laxative. (Editorial) *Internal Medicine World Report* 3:7, 1988.
23. Ewer, MS, Ali MK, Mansour G, Balakrishnan PV. Cardiac problems in ICU care of cancer patients. *The Journal of Critical Illness* 4:37-44, 1989.
24. Ali MK, Ewer MS. Cardiovascular problems in the patient with cancer: Effects of chemotherapy". *Primary Care & Cancer* 9:27-32, 1989.
25. Ali MK, Ewer MS. Cardiovascular problems in the patient with cancer: Radiation related heart disease". *Primary Care & Cancer* 9:11-5, 1989.

26. Ewer MS, Ali MK. Managing ischemic heart disease in a patient with cancer. *Primary Care & Cancer* 9:31-6, 1989.
27. Ewer MS. Philosophy of care decision making and ethical considerations. *Critical Care Clinics* 5:679-95, 1989.
28. Ewer MS, Truett L. Shock: Managing the septic syndrome in patients with cancer. *Primary Care & Cancer*. Reprinted in its entirety as Truett L, and Ewer MS Shock: Managing the Septic Syndrome in Patients with Cancer in *Dimensions in Oncology Nursing* 1989;3:9-13). 9:25-28, 1989.
29. Ewer MS, Ali MK. Incidence and management of pericardial problems in the cancer patient. *Primary Care & Cancer* 10:17-21, 1990.
30. Ewer MS. The suicide device: Does it really matter who pushes the button? . *Internal Medicine World Report* Vol 5(No 13):7, 1990.
31. Ewer MS. American Heart Association: Report from the 63rd Scientific Sessions. *Internal Medicine World Report* 6:3-4, 1991.
32. Ewer MS. Decision making in critical care oncology. *The Cancer Bulletin* 43:298-302, 1991.
33. Ewer MS. Decision making in critical illness: Who knows best? *Primary Care & Cancer*. 1992;12:79-81. (Reprinted from M.D. Anderson Oncology) 36:2 & 5, 1991.
34. Ewer MS. Decision-making in critical care oncology. *The Cancer Bulletin* 43:298-302, 1991.
35. Ewer MS. Decisions after Isis 3: Where do we go from here? *Internal Medicine World Report*. American College of Cardiology: News From the 40th Annual Scientific Session. 6:7-8, 1991.
36. Ewer MS. Ethical issues confronting today's physician: Directives to physicians. "Perspective on directives to physicians. *Internal Medicine World Report* 6:3-4, 1991.
37. Gibbs HR, Swafford J, Ewer MS, Ali MK. Cardiac Emergencies in the Cancer Patient. *Oncology (Williston Park)* 6(10):25-29, 10/1992. PMID: 1390012.
38. Ewer, MS Gibbs HR, Swafford J, Ali MK. Appropriate use of intensive care facilities in a cancer hospital. *The Cancer Bulletin* 44:168-172, 1992.
39. Ali, MK, Ewer MS, Gibbs HR, Swafford J. Cardiovascular emergencies in cancer patients. *The Cancer Bulletin* 44:173-184, 1992.
40. Ewer MS, Ali MK. Critical care for the cancer patient. *The Cancer Bulletin*. 44:163-164, 1992.
41. Ewer MS, Ali MK. Does pericardial effusion imply cardiac involvement in this man with lung cancer? *Primary Care & Cancer*. (this citation was updated in 1994 and is to be included in a compilation of similar articles in book form). 12:3, 1992.
42. Ewer MS. How would you manage hypertension in a man with prostate cancer? *Primary Care & Cancer*. 12:21, 1992.
43. Stokes, MJ, Gibbs HR, Swafford J, Zukiwski A, Ewer MS, Ali MK. Recurrent pericarditis secondary to bleomycin-vinblastine combination chemotherapy. *The Cancer Bulletin* 44:523-524, 1992.
44. Gibbs, HR, Swafford J, Ewer MS, Ali MK. Shock states sepsis syndrome and hemodynamic monitoring in the cancer patient. *The Cancer Bulletin* 44:185-191, 1992.
45. O'Hare, Ewer, MS, Hutcheson MA, Larson PJ, Pace JC, Stensland S. Multidisciplinary rounds. (Question regarding medical ethics answered). *Cancer Practice* 1:176-179, 1993.
46. Ewer MS. Richard M. Nixon: His Final Contribution. *Internal Medicine World Report* pp 4, 21, 31, 5/1994.
47. Ewer MS. American heart association 66th annual sessions: Is Minerva preparing to end her sojourn? *Internal Medicine World Report* 9 (No.1) pp3-5., 1994.
48. Ewer MS. American heart association 67th annual sessions: Are bigger clinical trials always better? *Internal Medicine World Report* 10(No. 1):3-5, 1995.
49. Ali, MK, Hanna, Ewer MS, Gibbs H, Swafford J, Lee K. CA-125 in the Diagnosis of Constrictive Pericarditis. *The Cancer Bulletin* 47:417-419., 1995.
50. Ewer, MS, Buzdar, A. Cancer in the Elderly. *The Cancer Bulletin* 47:187-188, 1995.
51. Ewer MS. Into the archives. *The Cancer Bulletin* 47:515-516, 1995.
52. Ewer MS. American heart association 68th annual sessions: Living and breathing cardiology. *Internal Medicine World Report* 11(1):pp 3-5, 1996.
53. Ewer MS, Jaffe N. Doxorubicin cardiotoxicity in children. *Acta Paediatrica de Mexico* 17:260-263, 1996.

54. Ewer MS. Report from the 32nd Annual sessions of the American Society of Clinical Oncology The sum may be more important than the Parts. *Internal Medicine World Report* 11(No. 13):pp 6-7., 1996.
55. Ewer MS. American heart association 69th annual sessions: Do we really need so many drugs? *Internal Medicine World Report*:pp 3-5., 1997.
56. Ewer MS. American heart association 70th annual sessions: Who pays for Drug Complications? *Internal Medicine World Report* 13:pp 1-3., 1998.
57. Ewer MS. American heart association 71st annual sessions: Is it time to think about macro ethics? *Internal Medicine World Report* 14(No. 1):pp. 1, 6.,1999.
58. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? *Semin Oncol* 26((suppl 12):):96-101, 1999.
59. Ewer MS. American heart association 72nd annual sessions: Cardiology at the millenium. *Internal Medicine World Report* (No.1):pp. 10-11, 2000.
60. Ewer MS. Ripeness and mootness in "Futility" policies. The University of Houston Law Center Health Law Website, 2001.
61. Ewer MS. Specialists must communicate in complex cases. *Internal Medicine World Report* 16(No 5):pp. 17, 2001.
62. Ewer MS. Perspectives on chemotherapy-related cardiotoxicity. *Oncology Forum (The Asian Journal of Cancer Care)* 6(3):2-4, 2002.
63. Ewer MS. Exercise echocardiography reflects cumulative anthracycline exposure during childhood. *Pediatric Blood Cancer* 42:554-555, 2004.
64. Ewer MS. Mammography in the elderly: You can't always draw a line in the sand. . *Internal Medicine World Report* 19(No 3):8, 2004.
65. Ewer MS. The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight. *European J Can*, 2007.
66. Ewer MS, Lenihan DJ. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? *Nat Clin Pract Oncol* 5(4):192-3, 4/2008. e-Pub 1/2008. PMID: 18212766.

Editorials

1. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the Anthracycline-Trastuzumab interaction. *J Clin Oncol* 28(25):3901-4, 9/2010. e-Pub 8/2010. PMID: 20679626.
2. Ewer MS, Ewer SM. Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC. *JTO Clin Res Rep*. 2021 Oct 13;2(10):100233. doi: 10.1016/j.jtocr.2021.100233. PMID: 34704082; PMCID: PMC8527046.

Other Articles

1. Ewer MS. *The Principles and Practice of Medicine*. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1978.
2. Ewer MS. *Harvey Cushing: The Life of Sir William Osler* 2. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1982.
3. Goldberg, SJ, Allen HD, Marx GR, Flinn CI: Philadelphia Lea & Febiger. *Doppler Echocardiography. Physical Principles and Clinical Applications* 2nd Edition. Hatle L, Angelsen B, Phila-delphia Lea & Febiger 331 pp. 1985. (reviewed together) Reviewed in the *Journal of Nuclear Medicine* 26 1221 1222 (1985):331 Reviewed in the *Journal of Nuclear Medicine* 26:1221-1222, 1985., 1985.
4. Ewer MS. *The Collected Essays of Sir William Osler* 3. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1985.
5. Ewer MS. *William Osler's Collected Papers on the Cardiovascular System*. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1985.
6. Halbert, DS. *Your Breast and You*. Vol. 39 (No. 1):238 pp. pp. 67 68, 1985.
7. Moosa AR, Martin C, Robson, Steven C (editors). *Comprehensive Textbook of Oncology*. Vol. 9::68-69., 1986.

8. Fozzard HA, Jennings RB, Raber E, Katz AM, Morgan HE editors. The Heart and Cardiovascular System. Scientific Foundations. Vol. 40(No. 2):pp. 111, 1986.
9. Ewer MS. Aequanimitas With Other Addresses to Medical Students Nurses and Practitioners of Medicine. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1987.
10. Kotler, MN, Steiner RM. Cardiac Imaging: New Technologies and Clinical Applications. Vol. 28:pg. 929, 1987.
11. Rosenthals JR, Smith C, Smith BD. Medical Care of the Cancer Patient. 39(180):461 pages, 1987.
12. Felix Jr W, Robert. Noninvasive Diagnosis of Peripheral Vascular Disease. 1987.
13. Banat Gabriel. The Mozart Violin Concerti: A Facsimile Edition of the Autographs with an Introduction. The Cancer Bulletin, 1987.
14. Ewer MS. Books for Holiday Gift-Giving. The Cancer Bulletin 41:340-343, 1989.
15. Ewer MS. Consuls and Ideals from the Writings of William Osler. the Classics of Medicine Library Birmingham Ala: Gryphon Editions Inc., 1989.
16. Abeloff Martin D. (Ed). Current Opinion in Oncology. Current Science. Reviewed in The Cancer Bulletin (42):366, 1990.
17. Koop, C Everett. Koop: The memoirs of America's family doctor 44:530-531, 1991.
18. Newman Art. The Illustrated Treasury of Medical Curiosa. 42:366, 1991.

Abstracts

1. Bekheit, Saad S, Ali MK, Ewer MS, Soto A, Blumenschein GR, Buzdar AU. Comparison of electrocardiography and echo-cardiography in early detection of Adriamycin cardiotoxicity. . Clin. Res. 26:744A, 1978.
2. Ali, MK, Bekheit Saad S, Ewer MS, Soto A, Buzdar AU, Blumenschein GR, Tashima CK, Wiseman CL, Hortobagyi GN, Maroongroge DP. Noninvasive evaluation of myocardial function in patients receiving Adriamycin chemotherapy. Proceedings of the the XII International Cancer Congress in Buenos Aires. Argentina Part 1:page 303, 1978.
3. Ali, MK, Mountain CF, Khalil KG, Ewer MS, Soto A, Maroongroge DP, Johnston D. Prediction of pulmonary function loss after lung resection for bronchogenic carcinoma. Proceedings of the XII International Cancer Congress in Buenos Aires Argentina Part 3:page 15, 1978.
4. Ali, MK, Mountain DF, Khalil KG, Soto A, Ewer MS, Maroongroge DP, Haynie TP. The function of the remaining pulmonary tissue following surgical resection for lung cancer: Serial follow up and preoperative prediction. Presented at the 44th Annual Scientific Assembly of the American College of Chest Physicians Washington DC & Chest 74:330, 1978.
5. Benjamin, RS, Ewer MS, MacKay B, Ali MK, Legha SS, Valdivieso M:. An endomyocardial biopsy study of anthracycline induced cardiomyopathy detection reversibility and potential amelioration. Proceedings of the American Association for Cancer Research Fifteenth Annual Meeting of the American Society of Clinical Oncology. New Orleans, La 20:372, 1979.
6. Ewer, MS, Ali MK, Wallace S, MacKay B, Mabry TC, Benjamin RS, Haynie TP. Cardiac biopsy and noninvasive cardiac studies in Adriamycin induced cardiomyopathy. Clin. Res. 28:414A, 1980.
7. Ali, MK, Mountain CF, Ewer MS, Atallah MR, Haynie TP. Pulmonary function in lung cancer, Correlation with disease stage and post surgical survival. . Proceedings of II World Conference of Lung Cancer Copenhagen Denmark:page 73, 1980.
8. Ewer, MS, Ali MK, MacKay B, Wallace S, Valdivieso M, Legha S, Tenezynski T, Benjamin R. A comparison of cardiac biopsy grades and ejection fraction estimation of patients receiving Adriamycin. J Am Soc Clin Oncolog C-135:page 366, 1981.
9. Legha, S, Benjamin R, Wang YM, MacKay B, Hortobagyi G, Buzdar A, Ewer M, Wallace S, Ali M. Evaluation of a Tocopherol against Adriamycin cardiotoxicity in humans. AACR. No. 700:page 176, 1981.
10. Ali MK, Ewer MS. Preoperative evaluation of pulmonary function. Communications to the Editor. Chest. 80:249, 1981.
11. Benjamin, R, Legha S, MacKay B, Ewer M, Wallace S, Valdivieso M, Rasmussen R, Blumenschein G, Freireich E. Reduction of Adriamycin using prolonged continuous intravenous infusion. AACR. No. 711:page 179, 1981.

12. Ali, MK, Atallah MR, Ewer MS, Mountain C, Dixon C, Johnston D, Hermes K, Haynie TP. Regional and overall pulmonary function changes in lung cancer: Correlations with tumor stage extent of pulmonary resection and patient survival. *Chest* 80:357, 1981.
13. Legha, S, Benjamin R, MacKay B, Blumenschein G, Ewer M, Yap HY, Wallace S, Bodey G. Reutilization of Adriamycin in previously treated patients. *J Am Soc Clin Oncol* C-791:page 534, 1981.
14. Legha, SS, Benjamin RS, MacKay B, Yap HY, Wallace S, Ewer MS, Blumenschein GR, Freireich EJ. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. *Cancer* 49:1766, 1982.
15. Ali, MK, Cheng R, Buzdar A, Ewer M, Haynie TP. Non-invasive cardiac studies before and after Adriamycin containing adjuvant chemotherapy (FAC) for stages II and III breast cancer. *Proceedings 18th Annual Meeting of the American Society of Clinical Oncology St. Louis Missouri*. 1:page 77, 1982.
16. Casimir, M, Miller A, Ewer M, Fritsche HJr, Haynie T, Bodey G, Valdivieso M. Phase I clinical study of 24-hour continuous infusion (CI) adriamycin (ACLA) with cardiac and pharmacologic monitoring. *Proceedings 18th Annual Meeting of the American Society of Clinical Oncology St. Louis Missouri* 23:152, 1982.
17. Legha, SS, Benjamin RS, Ewer M, Mackay B, Wallace S. Reduction of adriamycin cardiotoxicity by continuous IV infusion. *13th Intl Cancer Cong Seattle Washington*:603, 1982.
18. Legha, SS, Benjamin RS, Ewer M, Mackay B, Wallace S, Valdivieso M, Bodey GP. Reduction of adriamycin cardiotoxicity by continuous IV infusion: the effect of duration of infusion on cardiotoxicity. *Am Assoc Cancer Res* 23:127, 1982.
19. Benjamin, RS, Chawla SP, Ewer MS, Wallace S, MacKay B, Carrasco CH, Legha SS, Mann G, Hortobagyi GN, Valdivieso M, Ali MK, Haynie III TP. Cardiac toxicity of high-cumulative-dose Adriamycin rapid or 24-96 hour continuous infusion. *Proceedings American Society of Clinical Oncology San Diego California* 2:40, 1983.
20. Santos, GD, Ewer MS, Balakrishnan PV, Ali MK. Echocardiographic evaluation of cardiac function in patients receiving Adriamycin chemotherapy. *Clinical Research Division Woodbury N. J* 31:855A, 1983.
21. Dixon, C, Ali MK, Ewer MS, Haynie TP. Effect on non-surgical treatment for lung cancer on overall and regional pulmonary function. *Clinical Research* 31:415A, 1983.
22. Hortobagyi, G, Frye D, Blumenschein G, Ewer M, Mackay B, Buzdar A, Yap H, Hug V, Fraschini G, Benjamin RS. FAC with adriamycin by continuous infusion for treatment of advanced breast cancer. *Am Soc Clin Oncol* 2:105, 1983.
23. Valdivieso, M, Ewer MS, MacKay B, Benjamin RS, Wallace M, Ali MK, Bodey GP. Lower cardiotoxicity of weekly Adriamycin (A) in adeno. Squamous cell lung cancer. *(ASCO). Proceedings American Society of Clinical Oncology San Diego California* 2:206, 1983.
24. Chawla, S, Mann G, Benjamin RS, Legha SS, Mackay B, Ewer MS, Ali MK, Carrasco CH, Hortobagyi GN, Wallace S, Valdivieso M, Kim EE, Haynie TP. Monitoring of Adriamycin cardiotoxicity beyond the conventional limits of 500 mg/m². *Am Assoc Cancer Res* 24:134, 1983.
25. Chawla SP, Benjamin RS, Legha S, Plager C, Papadopoulos NEJ, Ewer MS, MacKay B, Bodey GP, Wang A. Doxorubicin-An Active anthracycline in metastatic melanoma. *American Society of Clinical Oncology* 3:263, 1984.
26. Benjamin, RS, Chawla SP, Ewer MS, Carrasco CH, MacKay B, Haynie III TP, Yap HY, Blumenschein GR, Holmes F, Ali MK, Bodey GP. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy. *American Society of Clinical Oncology Toronto Ontario Canada*. 3:40, 1984.
27. Ali Mk, Ewer MS, Mountain Cf, Jackson JR. Preoperative Pulmonary Evaluation of Lung Cancer Patients. *Proceedings 28th Annual Clinical Conference on Cancer*:20-3, 1984.
28. Ali, MK, Ewer MS, Mountain CF, Jackson JR. Preoperative pulmonary evaluation of lung cancer patients. *Proceedings 28th Annual Clinical Conference on Cancer*:20-3, 1984.
29. Ali, MK, Ewer MS, Mountain CF, Jackson JR. Preoperative Pulmonary Evaluation of Lung Cancer Patients. *Proceedings 28th Annual Clinical Conference on Cancer*:20-3, 1984.

30. Ali, MK, Ewer MS, Atallah MR, Mountain CF, Dixon CL, Johnston DA, Haynie TP. Regional and overall pulmonary function changes in lung cancer: Correlations with tumor stage extent of pulmonary resection and patient survival. *Cancer* 56:279, 1984.
31. Ewer, MS, Ali MK, Chawla SP, Carrasco CH, Lamki L, MacKay B, Balakrishnan PV, Johnston DA, Benjamin RS. A comparison of resting and exercise ejection fractions with cardiac biopsy grades in patients receiving Adriamycin. *American Society of Clinical Oncology*. 4:27, 1985.
32. Ewer, MS, Chawla SP, Carrasco CH, MacKay B, Ali MK, Haynie TP III, Benjamin RS. Correlations of ejection fraction and biopsy grades in patients receiving Adriamycin. *Recent Advances in Chemotherapy Anticancer Section. Proceedings of the 14th International Congress of Chemotherapy*. Kyoto, Japan. University of Tokyo Press:251-2, 1985.
33. Ewer, MS, Ali MK, Atta MS, Morice RC, Balakrishnan PV. Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure. *Proceedings of IV World Conference on Lung Cancer Toronto Canada*:68, 1985.
34. Atta, MS, Morice RC, Ewer MS, Krisburg MJ, Balakrishnan PV, Ali MK. Predicting post pneumonectomy pulmonary function in lung cancer. *Clinical Research*. 33:462A, 1985.
35. Morice, RC, Atta MS, Fritsche HA, Krisburg MJ, Ewer MS, Ali MK. Carcinoembryonic Antigen (CEA) as a tumor marker in Bronchoalveolar Lavage (BAL). *Proceedings of ASCO* 5:23, 1986.
36. Atta, MS, Morice RC, Fritsche HA, Krisburg MJ, Ewer MS, Ali MK. Neuron specific enolase as a tumor marker in broncho-alveolar lavage. *American Federation of Clinical Research* 34:560A, 1986.
37. Ali, MK, Morice RC, Ewer MS, Atta MS, Borrall RL, Balakrishnan PV. Regional pulmonary ventilation and perfusion using Xenon 133 in patients with lung tumors. *Proceedings of 14th International Cancer Congress* 3:983, 1986.
38. Ewer, MS, Benjamin RS, Hong WK, Borrall RC, Paredes J, Ali MK. Electrocardiographic changes in patients receiving chemotherapy with 5 Fluorouracil and Cis platinum with and without diethyldithiocarbamate. *Proceedings 15th International Congress of Chemotherapy*. Istanbul, Turkey Vol 3(abstract number 555):page 717-9, 7/1987.
39. Ewer, MS, Reeves B, Stiles N, Balakrishnan PV, Ali MK. Treatment of renal failure with dialysis in the critically ill cancer patient. *Proceedings of American Society of Clinical Oncology* 6:273, 1987.
40. Ali, MK, Ewer MS, Balakrishnan PV, Haynie TP, Romsdahl MM, Borrall RC. Late effect of Adriamycin chemotherapy on myocardial function. *Chest* 94:165, 1988.
41. Ali, MK, Ewer MS, Balakrishnan PV, Romsdahl MM, Borrall RC. Myocardial and pericardial changes following Adriamycin chemotherapy: Long term echocardiographic study. *Proceedings of the first International Conference on Supportive Care in Oncology Brussels Belgium*:45, 1988.
42. Balakrishnan, PV, Ali MK, Ewer MS, Stonecipher JV, Borrall RC. Pericardial effusion in cancer patients. *Proceedings of American Society of Clinical Oncology* 7:298, 1988.
43. Ewer, MS, Ali MK, Mansour G, Balakrishnan PV. Cardiac problems in ICU care of cancer patients. (Originally published in *J Crit Illness*. 1989, 4:37-44). This paper was abstracted in: *Cardiology Digest* 8:22-23, 1989.
44. Ewer MS. Philosophy of care decision making and ethical considerations. *Critical Care Clinics*. 5:679-95, 1989.
45. Ali MK, Ewer MS, Jarrett J, Spitzer G, Dunphy F, Abraham K, Borrall. Cardiotoxicity of mitoxantrone (Mitox) chemotherapy in patients previously treated with Adriamycin (ADRIA). *Proceeding of the 15th International Cancer Congress Hamburg Germany. Journal of Cancer Research and Clinical Oncology Part II to Volume 116*:page 32, 1990.
46. Ewer MS, Ali MK. Electrocardiographic (ECG) changes in patients receiving Mitoxantrone previously treated with Adriamycin. *Proceedings of American Society of Clinical Oncology*. 9:81, 1990.
47. Ali MK, Ewer MS, Borrall R. Late Adriamycin related myocardial dysfunction in pediatric patients. *56th Annual Scientific Assembly, Toronto Canada. Chest* 98:83S, 1990.
48. Ali, MK, Gibbs HR, Ewer MS, Swafford J, Husband K. Age-related late myocardial dysfunction following Adriamycin chemotherapy. *American Society of Clinical Oncology*. (abstract #24510):94, 1991.

49. Ewer, MS, Carrasco CH, Mackay B, Ali MK, Benjamin RS. Cardiac biopsy procedures at a Cancer Center. *American Society of Clinical Oncology* 10((abstract #1189)):336, 1991.
50. Ewer, M, Benjamin R. Cardiac toxicity of continuous infusion adriamycin. *Proceedings of the 2nd International Conference on Long-term complications of treatment of children and adolescents for cancer. Association for Research of Childhood Cancer Roswell Park Cancer Institute Buffalo New York*, 6/1992.
51. Gibbs, H, Ewer M, Holmes F, Swafford J, Ali M. Cardiac monitoring during administration of Taxol-Doxorubicin chemotherapy in patients with metastatic breast cancer: A preliminary report. *Proceedings of American Society of Clinical Oncology*(abstract #17011):86, 1992.
52. Ewer, MS, Taubert J, Ali MK. Advance directives in a tertiary cancer center intensive care unit. *Proceedings of the Fourth International Congress on Anti-Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France)*(abstract # 252):Page 121, 1993.
53. Ewer, MS, Legha S, Sella A Benjamin RS, Ali MK. Critical complications following Interleukin-2 (IL-2) alone and in combination with alfa-interferon (IFN) and conventional chemotherapy. *Proceedings of the American Society of Clinical Oncology (ASCO) Vol 12*(Abstract No. 413): Page 153, 1993.
54. Ali, MK, Ewer MS, Gibbs HR, Swafford J, Graff KL, Jaffe A, Cangir A, Thapar M. Effect of doxorubicin chemotherapy on diastolic cardiac function of pediatric patients. . *Proceeding of the 18th International Congress of Chemotherapy; (Abstract No 258), Stockholm (Sweden). (Abstract No 258)*, 1993.
55. Ewer, MS, Ali MK, Gibbs HR, Swafford J, Graff K, Jaffe N, Cangir, A. A Comparison of Diastolic Cardiac Function Parameters in Evaluating Pediatric Patients Treated With Anthracyclines. *XVI International Cancer Congress, New Delhi, India, UICC Abstract Book I, (Oral Presentations: Clinical-Chemotherapy Section) New Delhi, India*(Abstract OPCT2-05.):page 53, 10/1994.
56. Fonseca, G, Valero V, Walters R, Buzdar A, Willey J, Theriault R, Fraschini G, Ewer M, Tanzola C, Gordon D, Hortobagyi G. Phase II study of TLC D-99 (liposomal) doxorubicin in patients with metastatic breast carcinoma. *Proceedings of the American Society of Clinical Oncology (ASCO), Vol 13*((Abstract No. *60)): page 66, 1994.
57. Fonseca, GA, Valero V, Buzdar A, Walters R, Willey J, Benjamin R, Ewer M, Mackay B, Gordon D, Hortobagyi G. Decreased cardiac Toxicity by TLC D-99 (Liposomal Doxorubicin) in the Treatment of Metastatic Breast Carcinoma. *Proceedings of the American Society of Clinical Oncology (ASCO) Vol 14*((Abstract No. *96)): page 99, 1995.
58. Ali, MK, Ewer MS, Gibbs HR, Swafford J, Graff K. Late Doxorubicin-Associated Cardiotoxicity in Children: The Possible Role of Intercurrent Viral Infection. *Capsules & Comments in Oncology Nursing* (This abstract is a summary of the paper by the same name published in *Cancer* 3:94-96, 1995).
59. Ewer MS. Medical Futility: Are we trying to define the wrong word? *Proceedings of the American Society of Clinical Oncology (ASCO) Vol 14*((Abstract No. 1793.):page 541, 1995.
60. Swain, SM, Whaley FS, Gerber MC, Ewer MS. Congestive Heart Failure after Doxorubicin-Containing Therapy in Advanced Breast Cancer Patients Treated with or without Dexrazoxan 9lcrf-187, ADR-5f29). *Proceedings of the American Society of Clinical Oncology (ASCO) Vol 15*((Abstract No.*1739.):page 536, 1996.
61. Ewer, MS Jaffe N, Ried H, Lee K, Ali MK. High Incidence of Cardiac Death Among Pediatric Patients Experiencing Myocardial Dysfunction Following Doxorubicin-Containing Chemotherapeutic Regimens. *Proceedings of the American Society of Clinical Oncology (ASCO) Vol.15*((Abstract No *359.):page 177, 1996.
62. Benjamin RS, Ewer MS. Alternate approaches to cardioprotection: schedule manipulation and doxorubicin analogues. *Proceedings of the Seventh International Congress on Anti-Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France)*(abstract # 37.), 1997.
63. Ewer MS, Benjamin RS. Anthracycline Cardiotoxicity: presentation, natural history, and clinical spectrum. *Proceedings of the Seventh International Congress on Anti--Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France)*(abstract # 39.), 1997.

64. Ewer MS, Benjamin RS. Cardiac Monitoring of patients receiving cardiotoxic drugs. Proceedings of the Seventh International Congress on Anti-Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France) (abstract # 38), 1997.
65. Swain, SM, Whaley FS, Vitek L, Gerber M, Ewer MS. Congestive Heart Failure after Doxorubicin Containing Therapy in Advanced Breast Cancer Patients Treated with or without Dexrazoxane (DZR) (ICRF-187, ADR-529). Proceedings of the Seventh International Congress on Anti-Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France) (abstract # 43.), 1997.
66. Kish, SK, Ewer MS, Price KJ, Keenan CH, Feeley TW. Outcome of Cardiopulmonary Resuscitation in Cancer Patients Admitted to an Intensive Care Unit in a Tertiary Cancer Center. The American College of Chest Physicians, Sixty-Fourth Annual International Scientific Assembly, The XIX World Congress on Diseases of the Chest Physicians. Chest Volume 114(Number 4):page 334S, 1998.
67. Ewer, MS, Kish SK, Price KJ, Feeley TW. The Outcome of Cancer Patients Undergoing Cardiopulmonary Resuscitation in a Tertiary Cancer Center. The American College of Chest Physicians, Sixty-Fourth Annual International Scientific Assembly. The XIX World Congress on Diseases of the Chest Physicians. Chest, Volume 114(Number 4): page 334S, 1998.
68. Ewer, MS, Kish SK, Price KJ, Swafford J, Feeley TW. Mechanism of arrest as a predictor of survival following cardiopulmonary resuscitation in critically ill cancer patients. Proceedings of the Seventh International Congress on Anti-Cancer Chemotherapy, (Neoadjuvant, Adjuvant and Experimental). Paris (France), 1999.
69. Kish, S, Feeley TW, Price KJ, Ewer MS. Outcome and cost implications of cardiopulmonary resuscitation in the medical intensive care unit of a comprehensive cancer center. Supportive care in Cancer, April 1999 in press, 1999.
70. Ewer, MS, Sarris AH, Benjamin RS, Cabanillas FF. Cardiotoxic agent use in high risk cardiac patients: A pilot study. Eleventh International Congress on Anti-Cancer Treatment. Paris (France) (abstract number P204):page 254, 2001.
71. Ewer, MS, Durand J-B, Vooletich MT. Perspectives on chemotherapy-related cardiotoxicity. Oncology Forum (The Asian Journal of Cancer Care) 6(3):2-4, 2002.
72. Ewer, MS, Vooletich M, Valero V, Benjamin RS. Reversibility of trastuzumab-associated cardiotoxicity. Proceedings ESMO, Nice (France), 2002.
73. Ewer, MS, Vooletich M, Valero V, Higano CS, Benjamin RS. Trastuzumab (Herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations. Proceedings ASCO, 38th Annual Meeting (Abstract number 489). 2002.
74. Ewer, MS, Benjamin RS. Twelfth International Congress on Anti-Cancer Treatment. Paris (France, 2002).
75. Ewer, MS, Vooletich MT, Woods M, Durand JB, Lenihan DJ. Reversibility of trastuzumab-induced congestive heart failure in patients treated with anthracyclines. J Heart Failure 10: Supplement (August 2004) S117 (Abstract No. 369 from the 6th annual scientific meeting Heart Failure Society of America, Toronto Canada)., 9/2004.
76. Ewer, MS, Vooletich MT, Benjamin RS. A mathematical model for doxorubicin cardiotoxicity: Added evidence for the concept of sequential stress. Annual meeting proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23((abstract No. 2084.):148, 2004.
77. Valero, V, Gill E, Paton V, Chang H-Y, Buzdar AU, Park G, Hortobagyi GN, Ewer M. Normal cardiac biopsy results following co-administration of doxorubicin, cyclophosphamide and trastuzumab to woman with HER2 positive metastatic breast cancer. Annual meeting proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23((abstract No. 572)):20, 2004.
78. Buzdar, AU, Hunt K, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi GN. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: Initial results of a randomized trial in operable breast cancer with HER/2 positive disease. Annual meeting proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology 23(abstract No. 520):7, 2004.

79. Ewer MS, Benjamin RS. Formulae for predicting the likelihood of developing congestive heart failure following anthracycline chemotherapy: added evidence for early cardiotoxicity. *J Card Failure* 6 (Suppl):S159 (#259), 2005.
80. Ewer MS, Perez EA, Baselga J, et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. *St Gallen Primary Therapy of Early Breast Cancer 10th International Conference (#poster 176)*, Mar 14-17, 2007, 2007.
81. Storniolo AM, Koehler M, Preston A, Rappold E, Byrne J, Ewer MS. Cardiac safety in patients with metastatic breast cancer treated with lapatinib. *Proceedings of ASCO June 1-5, 2007* 25(18S):6 (#514), 2007.
82. Rastogi P, Jeong J, Geyer CE, Costantino JP, Romond EH, Ewer MS, Keefe DL, Levine T, Swain SM, Wolmark N. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide->paclitaxel compared to AC->T with trastuzumab. *Proceedings of ASCO June 1-5, 2007* 25(18S):6 (#513), 2007.
83. Ewer MS, Gluck S. Evaluation of lipid profiles and cardiovascular safety data of aromatase inhibitors. *ASCO Breast Cancer Symposium*, Washington, DC September 5-7, 2008, 2008.
84. Monnier A, Ewer MS. Update on the cardiovascular safety of aromatase inhibitors. *IMPAKT Breast Cancer Conference*, May 7-9, 2009, Brussels, Belgium (abstract #76P) (#76P), 5/2009.
85. Martell Re, Carcia-Manero G, Younes A, Ewer M, Daher Ln, Drouin M, Hunt W, Lortie K, Wilhelm J, Besterman J. Clinical development of MGcd0103, and isotype-selective HDAC Inhibitor: pericarditis/pericardial effusion in the context of overall safety and efficacy. *Blood* 114:4756, 2009.

Book Chapters

1. Ali MK, Mountain CF, Ewer MS, Johnston D, Haynie TP. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. In: *Chest*. Ch.5, 3. Med Publ. Inc, 68-70, 3/1980. PMID: 7357934.
2. Legha SS, Benjamin RS, MacKay B, Ewer M, Blumenschein G. Anthracycline Antibiotics in Cancer Therapy. In: *Role of Adriamycin in Breast Cancer and Sarcomas*. Martinus Nijhoff Publishers, 432-444, 1982.
3. Ali, MK, Mountain CF, Ewer MS, Johnston D, Haynie TP. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. In: *Pulmonary Diseases Reviews*. Ch. 12. A Wiley Med. Publ., 285-287, 1982.
4. Benjamin RS, Legha SS, Valdivieso M, Ewer MS, MacKay B, Wallace S. Reduction of adriamycin cardiac toxicity by schedule manipulation. In: *Anthracycline antibiotics in cancer therapy*. Ed(s) FM Muggia, CW Young, SK Carter. Martinus Nijhoff Publishers, 352-357, 1982.
5. Ewer MS, Chawla SP, Carrasco CH, MacKay B, Ali MK, Haynie TP III. Correlations of ejection fraction and biopsy grades in patients receiving Adriamycin. *Recent advances in chemotherapy anticancer section*. In: *Proceedings of the 14th International Congress of Chemotherapy Kyoto*. University of Tokyo Press, 251-252, 1983.
6. Chawla, SP, Benjamin RS, Legha SS, Ewer MS, Ali MK, Mackay B, Carrasco CH, Hortobagyi GN, Wallace S, Haynie III TP, Freireich EJ. Role of cardiac biopsy and radionuclide scan in monitoring of adriamycin induced cardiotoxicity. In: *13th International Congress of Chemotherapy*. Verlag H Egermann, 490, 1983.
7. Ali M Khalil, Ewer Michael S. *Cancer and the Cardiopulmonary System*. In: *M. D. Anderson Series on the Diagnosis and Management of Cancer*. Raven Press, 242 pages, 1984.
8. Benjamin, RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Haynie TP, Yap HY, Blumenschein GR, Holmes F, Ali MK, Bodey GP. Mitoxantrone cardiotoxicity: evaluation by nuclear angiography and endomyocardial biopsy. In: *Pharmanual*. Sieber & McIntyre, pp. 49-56, 1984.
9. Benjamin, RS, Chawla SP, Hortobagyi GN, Ewer MS, Mackay B, Legha SS, Carrasco H, Wallace S. Continuous infusion Adriamycin. In: *Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy*. Plenum Press, 19-25, 1986.

10. Ali, MK, Ewer MS, Morice RC, Mountain CF. Physiological Evaluation of the Patient with Lung Cancer. In: Lung Cancer: Current status and prospects for the future Annual Clinical Conference. University of Texas Press., pp. 99-104, 1986.
11. Benjamin, RS, Chawla SP, Ewer MS, Hortobagyi GN, Mackay SS, Legha SS, Carrasco CH, Wallace S. Organ Directed Toxicities of Anticancer Drugs. In: Adriamycin Cardiac Toxicity An Assessment of Approaches to Cardiac Monitoring and Cardioprotection. Martinus Nijhoff Publishers, 41 55, 1987.
12. Ewer MS, Naccarelli GV. Critical Care Clinics. In: Cardiac Critical Care xiii plus. Vol. 5, No 3, 241 pages, 1989.
13. Ewer MS. Inflammatory bowel disease in children: Quality-of-life issues and ethical considerations. In: Inflammatory Bowel Diseases and Morbus Hirschsprung (Chapter 16) Proceedings of the 65th International Falk Symposium Basel Switzerland April 10-11 1992. Ed(s) F Hadziselimovic, B Herzog. Kluwer Academic Press: Dordrecht/Boston/London, pp. 171-176, 1992.
14. Ali MK, Ewer MS. The natural history of anthracycline cardiotoxicity in children. In: Cancer treatment and the heart. Johns Hopkins University Press, pp 246-255, 1992.
15. Ewer MS, Benjamin RS. Cardiac complications . In: Cancer Medicine (3rd edition) (Chapter XL). Lea & Febiger, pp 2332-2348, 1993.
16. Ewer MS, Benjamin RS. Cardiac toxicity of antineoplastic therapy. In: Handbook of Chemotherapy in Clinical Oncology (second edition). Jersey (Channel Islands) Scientific Communication International Ltd, pp 447-452, 1993.
17. Ali, MK, Ewer MS, Gibbs HR, Swafford J, Graff KL, Cangir A, Jaffe N, Thapar M. Effect of Doxorubicin Chemotherapy on Diastolic Cardiac Function of Pediatric Patients. Recent Advances in Chemotherapy. In: Proceedings of the 18th International Congress of Chemotherapy, Stockholm, Sweden June 27-July 2, 1993; Washington D.C., 1994, American Society for Microbiology. Section VI, part 11, pages 956-957, 1993.
18. Ewer MS, Benjamin RS. Prevention of Cardiac Damage Due to Adriamycin: Modification of Method of Administration. In: Cardiac Toxicity after Treatment for Childhood Cancer. Wiley-Liss, pp 109-114, 1993.
19. Ewer, MS, Talbert J, Ali MK. Advance directives in the intensive care unit of a tertiary cancer center. In: Treatment, an Update (educational lectures and the texts of the main presentations of the Fourth International Cancer Congress, Paris, 1993). Springer-Verlag, Paris, pp 695-698, 1994.
20. Stone, RM, Essner R, Mundt AJ. Cancer Medicine Review (Contributor). Williams & Wilkins, 1997.
21. Ewer MS, Benjamin RS. Cardiac complications. In: Cancer Medicine (4th edition). Williams & Wilkins, pp 3197-3215., 1997.
22. Ewer MS, Benjamin RS. Cardiac complications. In: Cancer Medicine (5th edition) Chapter 149, pp. 2324-2339 (An extensive revision of the material published in the forth edition, see above. B. C. Decker, 2000.
23. Ewer MS, Benjamin. Cardiotoxicity of Chemotherapeutic Drugs. In: Chemotherapy Sourcebook, second edition. Chapter 33. Williams & Wilkins, pp 649-663, 2000.
24. Kilbourn, R, Fonseca G, Ewer M, Price K, Logothetis C, Griffith O. NG-monomethyl-L-arginine, an inhibitor of nitric oxide production, reverses interleukin-2-mediated hypotension in humans. In: Biology of nitric oxide., 2000.
25. Ewer MS, Benjamin RS. Cardiotoxicity of Chemotherapeutic Drugs . In: The Chemotherapy Sourcebook, third edition. Chapter 37. Lippincott Williams & Wilkins, pp.458-68., 2001.
26. Ewer, MS, Durand JB Yusuf SW, Swafford J. Emergency cardiac problems in the cancer patient. In: Emergency care of the cancer patient. BC Decker, 2002.
27. Ewer, MS, Benjamin RS, Yeh E. Cardiac Complications. In: Cancer Medicine. Chapter 152, 6th (an extensive revision of the material published in the 5th edition). B. C. Decker, pp.2525-2541, 2003.
28. Speyer JL, Ewer MS, Freedberg RS. Cardiac complications of chemotherapy. In: Clinical Oncology, 3rd. Ed(s) M Abeloff. Churchill Livingstone: Philadelphia, 2003.

29. Ewer MS, Speyer JL. Chemical cardioprotection against anthracycline cardiotoxicity. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 57-66, 2005.
30. Ewer MS, Benjamin RS. Doxorubicin cardiotoxicity: clinical aspects, recognition, monitoring, and prevention. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 9-31, 2005.
31. Gupta-Malhotra M, Steinherz LJ, Ewer MS. Pediatric cardiac neoplasia and cancer therapy-related cardiovascular disease. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 234-271, 2005.
32. Ewer MS, Henderson C, Martin FJ. Reduction of doxorubicin toxicity by the use of liposomal formulations of doxorubicin. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 43-73, 2005.
33. Ewer SM, Ewer MS. The pericardium in the cancer patient. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 493-507, 2005.
34. Suter TM, Ewer MS. Trastuzumab-associated cardiotoxicity. In: *Cancer and the Heart*, 1st. Ed(s) MS Ewer, ET Yeh. B. C. Decker: Hamilton, London, 67-74, 2005.
35. Ewer MS, Benjamin RS, Yeh E. Cardiac Complications. In: *Cancer Medicine*, 7th (an extensive revision of the material published in the 6th edition). Ed(s) JF Holland, E Frei III, JR Bast, DW Kufe, DL Morton, RR Weichselbaum. B. C. Decker: Hamilton, London, 2006.
36. Ewer MS, Ewer SM, Suter T. Cardiac complications. In: *Cancer Medicine*, 8th. Ed(s) JF Holland, E Frei III, JR Bast, DW Kufe, DL Morton, RR Weichselbaum. People's Medical Publishing House - USA: Shelton, CT, 2009.
37. Ewer MS, Suter TM. Diagnostic aspects of cardiovascular toxicity of antitumor drugs. In: *Cardiotoxicity of non-cardiovascular drugs*. Chapter 6. Ed(s) G Minotti. John Wiley & Son, 201-222, 2010.
38. Ewer MS, Yeh ETH. *Cancer and the Heart*, 2nd. In: *Cancer and the Heart*, 2nd, 2013.
39. Gallagher C, Ewer MS. *Cancer Ethics*. In: Elsevier. (In press), 2016.
40. Ewer MS, Ewer SM, Suter TM. Cardiac complications in Holland JF, Frei III, Bast JR, Kufe DW, Morton EL and Weichselbaum RR. In: *Cancer Medicine*. (In press), 9th, 2016.
41. Ewer MS. Ethical consideration of commercialism in healthcare. In: *Cancer Ethics*. Elsevier, 2017.
42. Ewer MS. Anthracycline Cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention. In: *Cancer and the Heart 3rd*, 2019.
43. Ewer MS. *Cancer and the Heart 3rd*. In: *Cancer and the Heart 3rd*, 2019.
44. Suter T, Ewer MS. Trastuzumab-Associated Cardiotoxicity. In: *Cancer and the Heart 3rd*, 2019.

Books (edited and written)

1. Ali M Khalil, Ewer MS. *Cancer and the Cardiopulmonary System*. Raven Press, New York, 1984.
2. *Cardiac Critical Care (Critical Care Clinics Vol 5, number 3; July 1989)*. WB Saunders, Philadelphia
3. Ewer MS, Yeh ET. Ed(s) MS Ewer, ET Yeh. *Cancer and the Heart*. In: *Cancer and the Heart*, 1st. BC Decker: Hamilton, London, 2005.
4. Ewer MS, Yeh ET. Ed. (Chinese translation of the first edition of this book 2006)
5. Ewer MS, Yeh ET. Ed(s) MS Ewer, ET Yeh. *Cancer and the Heart*. In: *Cancer and the Heart*, 2nd. People's Medical Publishing House - USA: Shelton, CT, 2012. PMID: 9781607950400.
6. Gallagher C, Ewer M. *Ethical Challenges in Oncology: patient care, research, education, and economics*. Elsevier Academic Press 2017
7. Ewer MS. *Cancer and the Heart*. 3rd Edition. People's Medical Publishing House - USA: Shelton, CT, 2019.
8. Gallagher C, Ewer M. *Ethical Challenges in Oncology* (first Japanese translation the book, 2020, published by arrangement with Elsevier)

Letters to the Editor

1. Ali M, Ewer MS. Preoperative Evaluation of Pulmonary Function. *CHEST*:249-250, 8/1981.

2. Chawla, SP, Benjamin RS, Legha S, Plager C, Papadopoulos NEJ, Ewer MS, MacKay B, Bodey GP, Wang A. Doxorubicin, an active anthracycline in metastatic melanoma. American Society of Clinical Oncology Toronto Ontario Canada 3:263, 1984.
3. Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well? J Clin Oncol 25:5532-5533, 2007.
4. Ewer MS, Ewer SM. Mechanisms underlying trastuzumab activity are complex. Nat Rev Cardiol, 2015 Sept 29, 2015.

Manuals, Teaching Aids, Other Teaching Publications

1. Ewer MS, Weinberg SL. Indications for Endomyocardial Biopsy". Accel Vol. 19, (10), 1987.

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Reviewer for multiple journals: Journal of Clinical Oncology, JACC, NEJM, (multiple other journals)

Member of Editorial Review Board

Member and book reviews editor, The Cancer Bulletin, 1985-1996

Member, Internal Medicine World Report, 1988-2009

Cardio-Oncology 2016-present

Member, Heart and Lung, 2003-09

Other Editorial and Review Activities

Guest Editor, Cancer Bulletin, Critical Care Issue, Vol.36, No.3, May-June, 1984

Editor, The Cancer Bulletin, 1987-1996

Guest Editor, Pitfalls and Controversies in Diagnosis and Treatment of Cancer, 1988

Coeditor, Critical Care Clinics, Critical Care Cardiology Vol. 5, No. 3, 1989

Guest Editor, Primary Care and Cancer-Cardiology Series, Cardiovascular Problems in Cancer Patient, 1989

Guest Editor, Internal Medicine World Report, American Heart Association Report 63rd Scientific Sessions Vol. 6 No. 1, 1991

Guest Editor, Internal Medicine World Report, Ethical Issues Confronting Today's Physician, Vol. 6, No. 11, Page 1,9, 1991

The Cancer Bulletin, Critical Care Volume 44 No. 3, 1992

Guest Editor, Internal Medicine World Report, American Heart Association Report 66th Scientific Sessions Vol. 9 No. 1, 1994

Guest Editor, The Cancer Bulletin, Cancer in the Elderly volume 46, No. 3, 1995

Editor, Oncology, 1996-1997

Editor, Internal Medicine World Report, 2000-2002

Guest Editor, Internal Medicine World Report, American Heart Association Report 72nd Scientific Sessions Vol. 16, 2000

Guest Editor, Internal Medicine World Report Clinical Quiz, 2000

Guest Editor, Internal Medicine World Report Medical-Legal Forum, 2000

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Nuclear Medicine Conference: Adriamycin Cardiotoxicity? Department of Nuclear Medicine

The University of Texas MD Anderson Cancer Center.
7/1/1996

1/1/1997

7/7/1998

ACLS in Perspective; Intravenous Techniques; Intravenous and Invasive Techniques Teaching Station
7/9/1992

Adriamycin Cardiotoxicity, an Update, M. D. Anderson Cancer Center, Houston, Texas
6/13/1994

Advanced Cardiac Life Support
1/1/1995

Advanced Cardiac Life Support
7/1/1995

Advanced Cardiac Life Support
1/1/1996

Advanced Cardiac Life Support (two-day course)
7/1/1994

Advanced life support in perspective, Myocardial infarction, Intravenous techniques, and Medico-legal, University of Texas M. D. Anderson Center ACLS program
7/1/1993

Medical Specialties conference: Adriamycin Cardiotoxicity, new ideas about an old problem
4/8/1996

Myocardial Infarction; Medicolegal Aspects of CPR and ECC; Mega Code Testing Station, The University of Texas MD Anderson Cancer Center
7/10/1992

Panel member, Conflict of Interest
3/17/2001

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Cardiac Arrhythmias

Invitee

MICU Rounds (Critical Care Medicine)

Veteran's Hospital, Houston

5/1/1994

Veteran's Hospital, Houston

7/1/1996

A Comparison of Diastolic Cardiac Function Parameters in Evaluation Pediatric Patients Treated with

11/2/1994

Acid Base Balance, Humana Southmore Hospital

4/7/1990

ACLS in Perspective, Veterans Administration Medical Center

10/26/1992

ACLS in Perspective and Invasive Techniques

1/25/1990

ACLS in Perspective; Intravenous Techniques; Automated External Defibrillation;

1/27/1992

ACLS in Perspective; Intravenous Techniques; Automated External Defibrillation; Intravenous Techniques

7/11/1991

Adriamycin by pulsed in fusion in children

5/21/1996

Adriamycin Cardiotoxicity: Continuous Infusion Administration to help Prevent Cardiotoxicity, Visiting Professor Lecture, University of Zurich

2/2/1995

Adriamycin Cardiotoxicity: Diagnosis, Treatment, and Prevention Through Administration Schedule Modi, Universitaetsklinikum Rudolf Virchow, Spandauer Damm 130, Berlin 14050 Berlin (Germany)

10/5/1994

Adriamycin Toxicity, University of Basel
6/26/1990

Advance Directives in a Tertiary Cancer Center, Hermann Hospital, Houston Texas
6/1/1994

Advance Directives in a Tertiary Cancer Center Intensive Care Unit
2/2/1993

Advanced Cardiac Life Support, Baycoast Medical Center, Baytown, Texas
4/1/1995

Anthracycline Associated Cardiotoxicity: New Thoughts Concerning Diagnosis and
Prevention, Visiting Professor at The Johns Hopkins Oncology Center, Baltimore, MD
10/27/1989

Appropriate Care for the Critically Ill Patient, The University of Texas Medical School
9/13/1990

Arrhythmias and AV Blocks
6/28/1988

Calcium Channel Blockers, MDACC
9/27/1988

Cardiac Concerns of Herceptin; Chicago, Ill.
10/1/2000

Cardiac Toxicity of Continuous Infusion Adriamycin
6/12/1992

Cardiovascular Pharmacology: Part I and II
1/27/1992

Critical Care for the Cancer Patient, MDACC
12/18/1989

Critical Care for the Cancer Patient: Decision making and philosophy of care, University of
Basel, Basel Switzerland
9/25/1995

Critical Care for the Cancer Patient: Decision making and philosophy of care, Visiting
Professor Lecture, University of Zurich
2/1/1995

Critical Care in Cancer Patients: The M. D. Anderson Experience
1/30/1993

Decision Making and Ethical Considerations at the End of Life, MDACC
9/6/1991

Decision Making and Ethical Considerations at the End of Life, MDACC
9/6/1991

Doxorubicin Cardiotoxicity, Recognition and prevention
2/4/1997

Ethical and Legal Issues of Weaning Patients, MDACC
3/16/1988

Ethics - Decision Making and Communication in Critical Patient Care, MDACC
1/23/1991

Ethics Involving Further Treatment of Terminal Patients
2/21/1995

Guidelines for Life Support
2/29/1988

Heart Failure Society of America

9/10/2000

Hypertension in the Cancer Patient, Sam Houston Memorial Hospital

11/22/1991

Hypertension in the Cancer Patient, Sam Houston Memorial Hospital

11/12/1991

Inflammatory Bowel Disease in Children: Quality-of-Life Issues and Ethical Considerations

4/10/1992

Intravenous Techniques and Medicolegal Aspects, Veterans Administration Medical Center

10/27/1992

Management Ethics

10/28/1988

Mechanism of Cardiac Complications in Patients Receiving Cancer Treatment., University of Hamburg, Department of Cardiology, Hamburg Germany

3/22/2001

Medical Ethics, Texas Women's University

11/6/1991

Medical Ethics, Texas Women's University

11/6/1991

Medical Ethics: A Three-Part Seminar on Medical Ethics

3/1/1994

Mortality & Morbidity, MDACC

10/14/1988

Myocardial Infarction and Medicolegal, San Jacinto College

4/8/1990

Myocardial Infarction and Medicolegal Aspects of CPR & ECC

1/26/1990

Myocardial Infarction; Medicolegal Aspects of CPR & ECC; Mega Code Testing Station

1/28/1992

Myocardial Infarction; Medicolegal Aspects of CPR and ECC; Mega Code Testing Station

7/12/1991

Philosophy of Care, Decision Making and Ethical Considerations

4/23/1991

Teaching Preceptor, Physical Diagnosis Course, The University of Texas School of Medicine, Houston, Texas

3/1/1995

Technological Extension of Life. Special Problems of the Irreversibly Ill and Severely Incapacitate

10/13/1988

Visiting Professor, The University of Freiberg (Germany)

10/23/1996

Visiting Professor, University of Munich, Munich Germany

7/6/1995

**Supervisory Teaching
Committees**

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Seventh International Congress on Anti-Cancer Treatment (*Septieme Congres International sur les traitements Anti-Cancereux*), Paris, France, Scientific Committee Member, 2/1997

Presentations at National or International Conferences

Invited

Ewer MS. How to evaluate the heart of the elderly patient, *Societe Internationale d'Oncologie Geriatrique* (SIOG), Berlin, Germany, 10/16/2009

Ewer MS. Cardiotoxicity in primary breast cancer: The role of advanced practice oncology nurses, Cardio BCa Syposia, Tampla, FL, 11/14/2009

Ewer MS. Cancer treatment-related cardiac dysfunction: Not just the same old heart failure, Israeli National Oncology Conference, Eilat, Israel, 1/13/2010

Ewer MS. Management of toxicities associated with anti-vascular agents, 8th International Symposium on Evolution of Supportive Care in Oncology: The Era of Targeted Agents, New York, NY, 2/20/2010

Ewer MS. Adult survivors of childhood cancer: What can we expect? Heart Failure 2010, Berlin, Germany, 5/30/2010

Ewer MS. Sunitinib-related hypertension in a randomized placebo-controlled trial of GIST patients - Poster Presentation, Pfizer, ASCO 2010, Chicago, IL, 6/6/2010

Ewer MS. Old and new cancer drugs, Jahrestagung der Schweizerischen Gessellschaft Fur Kardiologie (SKG), St. Gallen, Swaziland, 6/10/2010

Ewer MS. Appropriate care and DNR orders - who decides and how?, South African Heart Association Congress 2010, Sun City, South Africa, 8/9/2010

Ewer MS. Cardiotoxicity of anticancer agents - particularly in breast cancer - prevention, monitoring and treatment, South African Heart Association Congress 2010, Sun City, South Africa, 8/9/2010

Ewer MS. Treatment of acute cardiac disease in the cancer patient, South African Heart Association Congress 2010, Sun City, South Africa, 8/10/2010

Other, Including Scientific Exhibitions

Monnier A, Ewer MS. Update on the cardiovascular safety of aromatase inhibitors, IMPAKT Breast Cancer Conference, Brussels, Belgium, 5/7/2009

Seminar Invitations from Other Institutions

N/A

Lectureships and Visiting Professorships

Cardiology, Second Peking Hospital, Beijing, China, 2002
Cardiology, The University of Bern, Bern, Switzerland, 2005
Cardiology, The University of Bern, Bern, Switzerland, 2006
Cardiology, The University of Bern, Bern, Switzerland, 2007
Cardiology, University of Bern, Bern, Switzerland, 2008
Cardiology, The University of Bern, Bern, Switzerland, 2009
Cardiology, The University of Bern, Bern, Switzerland, 2010
Cardiology, The University of Bern, Bern, Switzerland, 2011

Other Presentations at State and Local Conferences

Ewer MS. Chemotherapy-related cardiac safety: Not just the same old cardiotoxicity, British Columbia Cancer Agency, Prince George, Canada, 10/6/2009
Ewer MS. Mitigating the risk of chemotherapy-associated cardiotoxicity in breast cancer patients, Med-IQ Webcast, Med-IQ, Baltimore, MD, 3/2/2010
Ewer MS. Ethics Lecture, Practical Updates in Oncology, US Oncology, Dallas, TX, 4/10/2010
Ewer MS. Chemotherapy-related cardiac safety: Not just the same old cardiotoxicity, Taussig Cancer Center Grand Rounds, Cleveland Clinic, Cleveland, OH, 5/7/2010
Ewer MS. Ethics committees in the modern era, Annual Community Oncology Research Forum, US Oncology, Dallas, TX, 8/28/2010

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American College of Emergency Physicians (Inactive)

American College of Physician's
Fellow
American Heart Association (Inactive)
Member
American Medical Association
Member
American Society of Clinical Oncology
Fellow
Critical Care Society (Inactive)
Member
Texas Medical Association Harris County Medical Society
Member

Local/State

N/A

UNIQUE ACTIVITIES

Director of the Advanced degree program in Health Law, University of Houston Law Center

DATE OF LAST CV UPDATE
11/10/22